Eloxx Pharmaceuticals, Inc.
ELOX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001035354
No open-market purchases or sales by Eloxx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $34.7M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Eloxx Pharmaceuticals, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 39 | 36 | −3 |
| Shares | 16.5M | 15.0M | −1.48M (−9.0%) |
| Value | $11.7M | $8.42M | −$3.25M (−27.9%) |
New holders (3)
Institutions that held Eloxx Pharmaceuticals, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Meeder Asset Management Inc | 28,531 | $16.0K | 0.00% |
| UBS Group AG | 21,849 | $12.0K | 0.00% |
| Jane Street Group, LLC | 20,354 | $11.0K | 0.00% |
Sold out (6)
Institutions that held Eloxx Pharmaceuticals, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Anson Funds Management LP | 553,652 | $391.0K |
| Occudo Quantitative Strategies LP | 29,492 | $21.0K |
| Rafferty Asset Management, LLC | 26,072 | $18.0K |
| Citadel Advisors LLC | 22,350 | $16.0K |
| Two Sigma Securities, LLC | 17,499 | $12.0K |
| Victory Capital Management Inc | 10,791 | $8.00K |